The United States’ National Aeronautics and Space Administration (NASA) has signed a development and commercialization agreement with Epiomed Therapeutics for intranasal scopolamine. The nasal spray for the treatment of motion sickness is also called INSCOP.
According to NASA, it has collected extensive data on motion sickness from the experience of astronauts in space and has found scopolamine to be an effective treatment. NASA published results from a trial of a gel formulation of INSCOP developed at the Naval Aerospace Medical Research Laboratory in Pensacola, FL in the journal Aviation, Space and Environmental Medicine in April 2010.
NASA Johnson Space Center scientist Lakshmi Putcha, who developed the treatment approach said, “NASA and Epiomed will work closely together on further development of INSCOP to optimize therapeutic efficiency for both acute and chronic treatment of motion sickness which can be used by NASA, the Department of Defense and world travelers on land, in the air and on the seas.”
Read the NASA press release.
